Although immune checkpoint inhibitors have shown significant clinical efficacy and long-lasting responses in patients with NSCLC, the overall response rate of anti-PD-1/PD-L1 therapy is only 20–30% (Borghaei et al., 2015; Herbst et al., 2019). This evidence concerns the gene CD274 and non-small cell lung carcinoma.